Walleye Capital LLC bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 88,148 shares of the biotechnology company's stock, valued at approximately $681,000. Walleye Capital LLC owned about 0.18% of REGENXBIO as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC increased its position in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,656 shares during the period. Barclays PLC grew its holdings in REGENXBIO by 141.3% during the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock worth $1,217,000 after acquiring an additional 67,948 shares during the period. Geode Capital Management LLC raised its position in shares of REGENXBIO by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company's stock worth $11,422,000 after acquiring an additional 44,037 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 2,510 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after purchasing an additional 296,700 shares in the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages have issued reports on RGNX. The Goldman Sachs Group dropped their price target on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Royal Bank of Canada reissued an "outperform" rating and set a $30.00 target price on shares of REGENXBIO in a research note on Tuesday, January 21st. Leerink Partners set a $24.00 price target on shares of REGENXBIO in a research note on Tuesday, March 18th. StockNews.com raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Finally, Raymond James initiated coverage on REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price for the company. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, REGENXBIO has a consensus rating of "Moderate Buy" and an average price target of $31.63.
Get Our Latest Analysis on RGNX
REGENXBIO Stock Up 17.2 %
RGNX stock opened at $7.82 on Wednesday. The stock's 50 day moving average is $6.81 and its 200-day moving average is $8.11. REGENXBIO Inc. has a twelve month low of $5.04 and a twelve month high of $17.52. The firm has a market capitalization of $391.91 million, a PE ratio of -1.55 and a beta of 1.26.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. On average, equities research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.
About REGENXBIO
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
